Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

----------------

Cash provided by financing

activities - $10,150 $36 $18,042

-------------------------------------------------------------------------

Funds from (purchases of)

short-term investments (1,427) (8,286) 6,201 (11,097)

Proceeds on disposal of

equipment - - 12 -

Purchases of property and

equipment (147) (30) (331) (201)

-------------------------------------------------------------------------

Cash provided by (used in)

investing activities $(1,574) $(8,316) $5,882 $(11,298)

-------------------------------------------------------------------------

(Decrease) increase in

cash and cash equivalents $(4,022) $(342) $(1,081) $(797)

Cash and cash equivalents,

beginning of period 5,886 5,288 2,945 5,743

-------------------------------------------------------------------------

Cash and cash equivalents,

end of period $1,864 $4,946 $1,864 $4,946

-------------------------------------------------------------------------

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of dermatological diseases (end of Phase II), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Addition
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... PureTech , a science and ... problems, announced today the closing of a $55 ... Invesco Perpetual, a $120 Billion group of funds. ... existing pipeline forward and to advance new healthcare ... creativity to really go for the big ideas ...
(Date:10/20/2014)... OR (PRWEB) October 20, 2014 Local ... participate in an investigational study of donor stem cells ... in stem cell therapy and has performed clinical stem ... this study is to determine if a single injection ... affected joints can help reduce pain and inflammation in ...
(Date:10/19/2014)... -- NextCODE Health, which enables clinicians and researchers to use ... announced the launch of its new genomic data analysis and ... Society of Human Genetics (ASHG) annual meeting in ... apply for free beta access, visit www.nextcode.com . A ... viewed here . The Exchange: ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report ... with analysis and forecast of revenue. This market is ... $208 million by 2019, at a Compound Annual Growth ... Browse through the TOC of the Asia-Pacific Speech Analytics ... analysis provided. It also provides a glimpse of the ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... EntreMed, Inc. (Nasdaq: ENMD ), a ... cancer today announced the presentation of clinical data for ... cancer patients.   The data were presented by the ... medical director of gynecologic oncology at Dana-Farber Cancer Institute ...
... LifeVantage Corporation (OTCBB: LFVN), the maker of ... reduction of oxidative stress by the synergistic activation ... review article involving Protandim® was published in the ... (Logo:   http://photos.prnewswire.com/prnh/20090930/LIFEVANTAGELOGO ) ...
... Houston researchers have developed a method for creating single-crystal ... the possibility of a replacement for silicon in high-performance ... their collaborators is featured on the cover of the ... a one-atom-thick layer of carbon that was first fabricated ...
Cached Biology Technology:EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4LifeVantage's Nrf2 Activator Reviewed for Tumor Prevention and Suppression in New Peer-Reviewed Article 2LifeVantage's Nrf2 Activator Reviewed for Tumor Prevention and Suppression in New Peer-Reviewed Article 3LifeVantage's Nrf2 Activator Reviewed for Tumor Prevention and Suppression in New Peer-Reviewed Article 4LifeVantage's Nrf2 Activator Reviewed for Tumor Prevention and Suppression in New Peer-Reviewed Article 5University of Houston develops method for creating single-crystal arrays of graphene 2
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... pandemic risk from strains of influenza virus increases with ... to become complacent that the most substantial threats have ... Influenza pandemics arise when a new virus strain – ... – spreads in the human population. There have been ... worst of which – the 1918 Spanish Flu – ...
(Date:10/15/2014)... in female mice to an enzyme activated by the ... resistant to respiratory infections than males. Now, an international ... bacterial pneumonia in female mice is linked to the ... that this enzyme is ultimately activated by the release ... lead by Professor Lester Kobzik at the Harvard University ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... , This release is available in German ... and spokesman for Solar Energy Research at Helmholtz-Zentrum Berlin (HZB), ... Solar Energy Conference and Exhibition" in Valencia. The EU Commission ... field of photovoltaics. The award ceremony took place ...
... Pine trees, scientists have shown that the iconic pine forests ... that colonised Britain after the end of the last Ice ... according to new results published in the journal Heredity ... team from the Centre for Ecology & Hydrology, the Polish ...
... Cotton growers can produce more cotton if they ... of an article published in the September-October 2010 ... of Agronomy. Bill Pettigrew, a scientist with the ... of cotton under irrigated and non-irrigated plots, with half ...
Cached Biology News:Untiring dedication to solar energy 2Scots Pine shows its continental roots 2Early cotton planting requires irrigation 2
...
Anti-Indolamine (Indoleamine) 2,3-dioxygenase Immunogen: Recombinant human IDO. Available Date: 38454...
Anti-Ephrin B1 Host: rabbit polyclonal Species Reactivity: human Applications: WB Storage: 4C...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
Biology Products: